Chemotherapy Induced Anemia - Pipeline Review, H1 2016

Published: Mar, 2016 | Pages: 66 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Anemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chemotherapy Induced Anemia - Pipeline Review, H1 2016', provides an overview of the Chemotherapy Induced Anemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Anemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Anemia
- The report reviews pipeline therapeutics for Chemotherapy Induced Anemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chemotherapy Induced Anemia therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Anemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Anemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chemotherapy Induced Anemia Overview 7
Therapeutics Development 8
Pipeline Products for Chemotherapy Induced Anemia - Overview 8
Chemotherapy Induced Anemia - Therapeutics under Development by Companies 9
Chemotherapy Induced Anemia - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Chemotherapy Induced Anemia - Products under Development by Companies 13
Chemotherapy Induced Anemia - Companies Involved in Therapeutics Development 14
3SBio Inc. 14
BIOCAD 15
Dr. Reddy's Laboratories Limited 16
Panacea Biotec Limited 17
Pfizer Inc. 18
Sandoz International GmbH 19
SBI Pharmaceuticals Co., Ltd. 20
Therapure Biopharma Inc. 21
Tolero Pharmaceuticals, Inc. 22
Vifor Pharma AG 23
Chemotherapy Induced Anemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
(aminolevulinic acid hydrochloride + sodium ferrous citrate) - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
darbepoetin alfa - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
darbepoetin alfa - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
darbepoetin alfa - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
darbepoetin alfa - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
epoetin alfa - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
epoetin zeta - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ferric carboxymaltose - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
PRS-080 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SSS-06 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
TBI-304H - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
TP-0184 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TP-0413 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
TXA-302 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Chemotherapy Induced Anemia - Recent Pipeline Updates 53
Chemotherapy Induced Anemia - Dormant Projects 58
Chemotherapy Induced Anemia - Discontinued Products 59
Chemotherapy Induced Anemia - Product Development Milestones 60
Featured News & Press Releases 60
Mar 11, 2015: Therapure Innovations Receives FDA Approval to Proceed with a Phase 1 Clinical Trial of Its Novel Anemia Therapeutic TBI 304H 60
Oct 30, 2012: SBI Pharmaceuticals Submits a Phase-1 Clinical Trial CTA to MHRA for a Drug to Treat Cancer Chemotherapy-induced Anemia 60
Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 60
Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 61
Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 61
Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 62
Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 62
Aug 09, 2010: Dr Reddy's Launches Darbepoetin Alfa For Treatment Of Anemia In India 63
Dec 01, 2008: International presentation of clinical safety and efficacy data for Binocrit, the world's first complex biosimilar 63
Jan 07, 2008: Sandoz and Gambro form strategic alliance 64
Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables
Number of Products under Development for Chemotherapy Induced Anemia, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Chemotherapy Induced Anemia - Pipeline by 3SBio Inc., H1 2016 14
Chemotherapy Induced Anemia - Pipeline by BIOCAD, H1 2016 15
Chemotherapy Induced Anemia - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 16
Chemotherapy Induced Anemia - Pipeline by Panacea Biotec Limited, H1 2016 17
Chemotherapy Induced Anemia - Pipeline by Pfizer Inc., H1 2016 18
Chemotherapy Induced Anemia - Pipeline by Sandoz International GmbH, H1 2016 19
Chemotherapy Induced Anemia - Pipeline by SBI Pharmaceuticals Co., Ltd., H1 2016 20
Chemotherapy Induced Anemia - Pipeline by Therapure Biopharma Inc., H1 2016 21
Chemotherapy Induced Anemia - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 22
Chemotherapy Induced Anemia - Pipeline by Vifor Pharma AG, H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Assessment by Combination Products, H1 2016 25
Number of Products by Stage and Target, H1 2016 27
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Chemotherapy Induced Anemia Therapeutics - Recent Pipeline Updates, H1 2016 53
Chemotherapy Induced Anemia - Dormant Projects, H1 2016 58
Chemotherapy Induced Anemia - Discontinued Products, H1 2016 59